Rare Disorders Series II (Hypoparathyroidism) Treatment Market is Expected to Reach $1.09 bn by 2026
The Hypoparathyroidism Treatment Market was valued at US$658.58 million in the year 2018 and is estimated to reach US$1.09 billion by 2026, at a CAGR of 7.57%.
Hypoparathyroidism is classified as a rare endocrine disorder characterized by failure in producing the required amount of parathyroid hormone or the produced hormone cannot participate in biological activities. Generally, the parathyroid hormone regulates calcium and phosphorus in the blood, determines bone cell activity and bone growth. An abnormality in the parathyroid gland can result in hypocalcaemia, hyperphosphatemia, etc. The abnormality can be caused due to several factors that include the autoimmune process, surgical removal of the parathyroid gland, genetic abnormalities, or causes unknown (idiopathic).
The onset of hypoparathyroidism is around 43±5 years. The epidemiological data suggest that the disorder is more prevalent in western countries such as the US (37 per 100000), Denmark (22 per 100000), Norway (10.2 per 100000). Further, the ratio of hypoparathyroidism in female to male population is 3:1. In the US, the female population accounts for more than 71% of the total hypoparathyroidism population with the total number of cases already crossing 81000 by 2018. Among the affected population, 95% of the incidence can be attributed to postsurgical hypoparathyroidism. With a drastic change in the lifestyle and increasing geriatric population, the number of thyroid surgeries is increasing due to alterations in endocrine functions. In recent times, the patients are screened more for thyroid and parathyroid based disorders very frequently. The R&D companies are also investing more to identify the best treatment modalities to reduce the impact of the disorders. These factors are expected to drive market growth throughout the forecast period.
North America and European regions are expected to contribute more towards the market share with increasing disease prevalence, presence of key players in the region and more R&D investments. The APAC & LAMEA regions have contributed less. However, increasing lifestyle changes may increase the contribution of these regions to the market share.
The treatment for hypoparathyroidism is to maintain the serum calcium, phosphorus, and magnesium within the allowed range. The standard treatment comprises of vitamin D2 and D3 supplements, and calcium supplements. On a longer run, parathyroid hormone under the hormonal therapy regimen is prescribed. Vitamin D therapy leads the market share among the hypoparathyroidism treatment followed by parathyroid hormone therapy and calcium supplementation. The main challenge faced during treatment is the length of the treatment, adherence, efficacy, and effectiveness of the treatment as it is purely based on clinical judgment and experience.
Companies such as Takeda and Roche are major players in the market with more prescriptions on Natpara and Rocaltrol, respectively. But recently, Takeda had to call back Natpara in the US owing to the presence of rubber particulates originating from the rubber septum of the NATPARA cartridge. There are also companies Ascendis Pharma, Aerami Therapeutics, Extend Biosciences, Entera Bio, etc. which have drugs at various stages of development. To date, there are 92 clinical trials reported in clinicaltrials.gov for hypoparathyroidism.
Request for Sample Pages @ https://www.optimainsights.org/sample-request/207-hypoparathyroidism-treatment-market
The Hypoparathyroidism Market Report is segmented based on Drug Class (Parathyroid hormone, Vitamin D & Calcium Supplement), By Route of Administration (Oral & Parenteral), By Distribution Channel (Hospital, Retail & Online Pharmacies) and By Region (North America, Europe, APAC and LAMEA).
The Hypoparathyroidism market analytics report from Optima Insights is a part of the Second Series on Rare Disorders consisting of a detailed analysis on the epidemiology, products, pipeline drugs, key drivers & restraints, challenges, reimbursement policies on the inherited metabolic disorders that require more attention. Further, every part of the rare metabolic disorder series will cover 10 disorders categorized based on country prevalence and occurrence.
• Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
• Provides a Comparative Analysis of Key Marketed and Pipeline Products.
• Provides Key Information on Players involved.
• Provides a Complete Overview of Market Segments and the Regional Outlook.
• Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Hypoparathyroidism Market, 2015 to 2017
- Forecast of the Hypoparathyroidism Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Hypoparathyroidism Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)